SuperCom, a global provider of IoT, cybersecurity, and digital identity solutions, will hold a conference call on November 12, 2026, to discuss its financial results for the third quarter ended September 30, 2026. The company will release its financial results in a press release before the call, which will include a Q&A session with management. This event is important for investors to understand SuperCom's recent performance and outlook. SuperCom specializes in secure IoT devices, cybersecurity software, and e-Government solutions worldwide.
SuperCom's upcoming Q3 2026 financial results provide context for technology sector performance on Pluang. As of November 6, 2026, 81 of 150 priced US technology stocks rose while 68 fell. Notable movers include Akamai Technologies at USD 84.79 with an 8.93% increase and a typical hold time of 46 days, Cloudflare Inc at USD 267.00 up 8.90% with a 70% buy order activity, and Arista Networks at USD 173.15 rising 8.79% with 95% buy orders and a 55-day hold time.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
